Kevin Dennis Green Sells 127,544 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 127,544 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $211,723.04. Following the sale, the chief financial officer owned 1,040,551 shares in the company, valued at approximately $1,727,314.66. The trade was a 10.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

• On Thursday, March 5th, Kevin Dennis Green sold 55,225 shares of Cerus stock. The stock was sold at an average price of $2.06, for a total value of $113,763.50.
• On Friday, March 6th, Kevin Dennis Green sold 27,796 shares of Cerus stock. The stock was sold at an average price of $2.01, for a total value of $55,869.96.

Cerus Price Performance

Shares of CERS opened at $1.80 on Wednesday. The firm has a market cap of $345.91 million, a PE ratio of -22.50 and a beta of 1.51. Cerus Corporation has a 52-week low of $1.12 and a 52-week high of $2.96. The business’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $1.88. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $64.58 million during the quarter, compared to the consensus estimate of $59.31 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. On average, equities analysts anticipate that Cerus Corporation will post -0.08 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on CERS shares. Wall Street Zen downgraded shares of Cerus from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. TD Cowen reissued a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Finally, Zacks Research downgraded Cerus from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Key Cerus News

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Cerus named COO Vivek Jayaraman as President & Chief Executive Officer effective July 1, 2026, with current CEO William “Obi” Greenman becoming Executive Chairman — a clear, pre‑announced succession that typically reduces leadership uncertainty. Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
• Positive Sentiment: Large institutional investors have been increasing positions recently (notably AQR, UBS and Millennium), which can support liquidity and signal professional investor interest.
• Neutral Sentiment: The company disclosed executive compensation adjustments tied to the leadership change; these may be neutral-to-slightly-positive if they align incentives, but they could also increase near‑term dilution depending on grant size and vesting. Compensation Changes
• Negative Sentiment: Multiple insiders sold sizable blocks around $1.66: CEO William Greenman (~447,757 shares), incoming CEO/COO Vivek Jayaraman (~165,200), CFO Kevin Green (~127,544), Richard Benjamin (~101,740) and Chrystal Jensen (~113,008). Collective insider liquidations of this scale can create short‑term downward pressure and raise questions about timing or liquidity needs. CEO SEC Filing Benjamin SEC Filing
• Negative Sentiment: Analyst coverage is mixed-to-negative: recent downgrades (Wall Street Zen cut buy→hold; Zacks to strong sell) leave the consensus at a “Reduce” rating, which can limit upside from new buyers until sentiment improves.

Institutional Investors Weigh In On Cerus

A number of hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its holdings in shares of Cerus by 321.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 46,801 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 35,692 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Cerus by 28.8% in the 4th quarter. Invesco Ltd. now owns 309,168 shares of the biotechnology company’s stock worth $637,000 after purchasing an additional 69,087 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Cerus by 48.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 53,028 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 17,336 shares in the last quarter. Engineers Gate Manager LP grew its position in Cerus by 4.7% in the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 6,415 shares during the period. Finally, Kotler Kevin bought a new stake in Cerus during the 4th quarter valued at $2,084,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.